An investigational antibody-drug conjugate, QLS5132, showed a 50% objective response rate in patients with advanced platinum-resistant ovarian cancer in a phase I trial.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
New antibody-drug conjugate shows clinical benefit for advanced platinum-resistant ovarian cancer
94.4% disease control rate
50% objective response rate
9 patients with partial response